Michael J. Brennan, M.D., F.A.C.P.; Robert W. Talley, M.D., F.A.C.P.; J. H. Burrows, M.D.
This content is PDF only. Please click on the PDF icon to access.
Six hundred patients have been treated with 5-Fluorouracil for disseminated neoplastic disease by the staff of one chemotherapy unit over the past 6 years.
The drug has been shown to give an objective remission rate in the order of 15 to 20% in mammary gastric, hepatic, colo-rectal, and ovarian cancer. Objective remission connotes at least 25% decrease in diameter of more than 50% of measurable lesions, persisting for at least 2 months and associated with improvement in activity status and lessening of symptomatology.
The mean duration of regressions observed in these "responsive" categories of clinical cancer has been approximately 5
Michael J. Brennan, Robert W. Talley, J. H. Burrows. The Place of 5-Fluorouracil in Medical Oncology.. Ann Intern Med. 1965;62:1078. doi: 10.7326/0003-4819-62-5-1078_2
Download citation file:
Published: Ann Intern Med. 1965;62(5):1078.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use